YM17E 是一种酰基辅酶a:胆固醇酰基转移酶 (ACAT) 的抑制剂，在兔肝微粒体的体外实验中，IC₅₀ 值为 44 nM。

YM17E is an inhibitor of acyl CoA:cholesterol acyltransferase (ACAT), with IC 50 of 44 nM in rabbit liver microsomes in vitro.

Solid

IC50: 44 nM (ACAT in rabbit liver microsomes)

YM17E is as potent in inhibiting ACAT activity in the liver as in the intestine, with IC50 values of 45 and 34 nM, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.

YM17E (3, 10 and 30 mg/kg per day, p.o.) decreases total cholesterol, cholesteryl ester and non-HDL cholesterol in a dose-dependent manner. Total cholesterol and cholesteryl ester levels in liver do not decrease significantly after intravenous administration of YM17E, but do decrease significantly and in a dose-dependent manner after oral administration. YM17E (3, 5, 10 mg/kg, i.v.) significantly inhibits hepatic ACAT activities in a dose-dependent manner. YM17E produces a significant increase in I-LDL clearance in atherogenic diet-fed rats after both oral and intravenous administration. YM17E inhibits production of [C]cholesteryloleate from [C]oleoyl CoA in a dose-dependent manner in both liver and intestinal microsomes used as enzyme sources. has not independently confirmed the accuracy of these methods. They are for

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；In solvent -80°C 6 months

[1]. Uchida T, et al. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats. Atherosclerosis. 1998 Mar;137(1):97-106.
[2]. Kashiwa M, et al. Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol. 1997 Jan;73(1):41-50.

In Vitro: DMSO : ≥ 125 mg/mL (191.45 mM)配制储备液